Lowering Cholesterol, Increasing the Impact: The Case for Earlier Action to Address the CV Epidemic
This event will gather global health leaders and policymakers to address the critical need to shift cardiovascular care from late-stage crisis management to proactive, early intervention.
The discussion will center on the mounting clinical and economic evidence supporting the “lower for longer” approach to lipid management. Experts will examine how cumulative exposure to LDL cholesterol drives the progression of atherosclerotic cardiovascular disease (ASCVD). Beyond the clinical data, the event will explore the broader health technology assessment (HTA) and policy implications of earlier cardiovascular intervention. Participants will analyze the cost-effectiveness of modern therapies and discuss strategies to overcome systemic barriers to patient access.
Objectives
- Present evidence on the health benefits of reducing LDL cholesterol earlier in life to prevent the cumulative damage of ASCVD.
- Analyze the long-term cost-effectiveness and health system value of early pharmacological intervention compared to traditional “wait and see” models.
- Provide actionable insights for policymakers and HTA bodies to update guidelines that support broader access to lipid-lowering therapies.
- Identify and address the practical barriers that prevent clinicians from optimizing cardiovascular care according to the latest research.
Space is limited for this event. To learn more or register your interest, please fill out the form linked at the Register button